2022 Consensus Statement on the Management of Familial Hypercholesterolemia in Korea

Lee, Chan-Joo; Yoon, Minjae; Kang, Hyun–Jae; Kim, Byung Jin; Choi, Sung Hee; Jeong, In‐Kyung; Lee, Sang‐Hak

doi:10.12997/jla.2022.11.3.213

Cited by 3 publications

(3 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The limitations of this study include a lack of detailed clinical data about dyslipidemia, such as familial history, comorbidities, and lipid-lowering medications [ 4 , 19 , 29 ]. The physiological relevance of the prediction model is constrained by the limited availability of detailed clinical information, including data on cardiovascular disease endpoints such as heart attacks, emphasizing the necessity for further exploration in future research.…”

Section: Discussionmentioning

confidence: 99%

Development and Validation of Multiple Equations for Low-Density Lipoprotein and Apolipoprotein B in Korean Patients Visiting Local Clinics and Hospitals

Choi

Lee

2023

Nutrients

View full text Add to dashboard Cite

We investigated the utilization of apolipoprotein B (ApoB), an independent risk factor for cardiovascular disease, and developed and validated a translational equation for calculating low-density lipoprotein cholesterol (LDL-C) in the Korean population visiting local clinics and hospitals. Among a total of 469,520 data sets of the lipid profile panel (total cholesterol, triglycerides, and high-density lipoprotein cholesterols), 142,932 lipid test sets with data on LDL-C and/or ApoB were used for statistical analysis. Using linear regression analysis, we created ApoB percentile value-derived LDL-C equations in a creating set and validated them with previously reported equations (a total of 11 equations) in comparison to directly measured LDL-C using two independent validating sets. Among all lipid test sets, the simultaneously measured ApoB test only accounted for 2.0%, indicating its underutilization in Korea. The ApoB-derived equations, which were derived in this study and previous studies, showed an overall agreement of ≥94.3% for NCEP ATP III criteria. However, the accuracy of the equations varied among data sets of populations. Future studies are needed to validate translational equations for ApoB and LDL-C in different populations to clarify the clinical implications of these equations.

show abstract

Section: Discussionmentioning

confidence: 99%

Development and Validation of Multiple Equations for Low-Density Lipoprotein and Apolipoprotein B in Korean Patients Visiting Local Clinics and Hospitals

Choi

Lee

2023

Nutrients

View full text Add to dashboard Cite

show abstract

“… 1 2 3 This pharmacotherapy is recommended with high classes in diverse guidelines on lipid-lowering therapy. 4 5 In the revised guidelines of the past decade, LDL-C treatment targets have been steadily lowered for high- and very high-risk groups. 6 As a result, high-intensity statins are frequently prescribed and many more patients require combination drugs, such as ezetimibe.…”

Section: Introductionmentioning

confidence: 99%

“…Ezetimibe is the most common option when the treatment goal is not achieved using statin monotherapy or when an individual experiences a drug intolerance. 4 6 …”

Section: Introductionmentioning

confidence: 99%

Moderate-Intensity Rosuvastatin/Ezetimibe Combination versus Quadruple-Dose Rosuvastatin Monotherapy: A Meta-Analysis and Systemic Review

Kang,

Park,

Lee

2024

Yonsei Med J

Self Cite

View full text Add to dashboard Cite

Purpose There are few studies in the literature on the dosage of statin that equivalently reduces low-density lipoprotein cholesterol (LDL-C) compared to an ezetimibe combination and whether such regimens have differences in safety. We compared the lipid-modifying efficacy and safety of 5 mg rosuvastatin/10 mg ezetimibe to those of 20 mg rosuvastatin. Materials and Methods A literature search was conducted using the PubMed, EMBASE, Cochrane, Web of Sciences, and SCOPUS databases up to December 2021. Human studies investigating the two aforementioned regimens with a randomized controlled design were selected. Outcome variables included the percentage reduction in LDL-C and other lipid parameters and rates of composite adverse events (AEs), including muscle-related symptoms. A random-effects meta-analysis was performed after heterogeneity testing between studies. Results Seven studies were included in this meta-analysis. The percentage LDL-C reduction did not differ between the combination and monotherapy groups [standardized mean difference (SMD) 0.08; 95% confidence interval (CI) -0.09 to 0.26; p =0.35]. The risk of composite AEs (odds ratio 0.50; 95% CI 0.15 to 1.72; p =0.27) of the combination was not different compared to the monotherapy group. The percentage of total cholesterol reduction was greater in the combination group (SMD 0.22; p =0.02), whereas that of triglyceride reduction and high-density lipoprotein cholesterol elevation did not differ between the two groups. Conclusion This meta-analysis showed that 5 mg rosuvastatin/10 mg ezetimibe had largely comparable lipid-modifying efficacy and tolerability as 20 mg rosuvastatin.

show abstract

Advancing Familial Hypercholesterolemia Detection and Management in South Korea

Bae

2024

Korean Circ J

View full text Add to dashboard Cite

2022 Consensus Statement on the Management of Familial Hypercholesterolemia in Korea

Cited by 3 publications

References 51 publications

Development and Validation of Multiple Equations for Low-Density Lipoprotein and Apolipoprotein B in Korean Patients Visiting Local Clinics and Hospitals

Development and Validation of Multiple Equations for Low-Density Lipoprotein and Apolipoprotein B in Korean Patients Visiting Local Clinics and Hospitals

Moderate-Intensity Rosuvastatin/Ezetimibe Combination versus Quadruple-Dose Rosuvastatin Monotherapy: A Meta-Analysis and Systemic Review

Advancing Familial Hypercholesterolemia Detection and Management in South Korea

Contact Info

Product

Resources

About